메뉴 건너뛰기




Volumn 14, Issue 12, 2013, Pages 1575-1584

Statin therapy on glycaemic control in type 2 diabetes: A meta-analysis

Author keywords

Glycaemic control; Meta analysis; Statin; Type 2 diabetes

Indexed keywords

ATORVASTATIN; C PEPTIDE; CERIVASTATIN; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; ROSUVASTATIN; SIMVASTATIN;

EID: 84880265383     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.810210     Document Type: Article
Times cited : (27)

References (43)
  • 1
    • 26244432388 scopus 로고    scopus 로고
    • Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins
    • Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78
    • (2005) Lancet , vol.366 , pp. 1267-1278
    • Baigent, C.1    Keech, A.2    Kearney, P.M.3
  • 2
    • 38049033935 scopus 로고    scopus 로고
    • Efficacy of cholesterol-lowering therapy in 18, 686 people with diabetes in 14 randomised trials of statins: A meta-analysis
    • Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117-25
    • (2008) Lancet , vol.371 , pp. 117-125
    • Kearney, P.M.1    Blackwell, L.2    Collins, R.3
  • 3
    • 35748962429 scopus 로고    scopus 로고
    • The safety of statins in clinical practice
    • Armitage J. The safety of statins in clinical practice. Lancet 2007;370:1781-90
    • (2007) Lancet , vol.370 , pp. 1781-1790
    • Armitage, J.1
  • 4
    • 4344683381 scopus 로고    scopus 로고
    • Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial
    • Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96
    • (2004) Lancet , vol.364 , pp. 685-696
    • Colhoun, H.M.1    Betteridge, D.J.2    Durrington, P.N.3
  • 5
    • 33746428470 scopus 로고    scopus 로고
    • Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: The Treating to New Targets (TNT) study
    • Shepherd J, Barter P, Carmena R, et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 2006;29:1220-6
    • (2006) Diabetes Care , vol.29 , pp. 1220-1226
    • Shepherd, J.1    Barter, P.2    Carmena, R.3
  • 6
    • 20944448451 scopus 로고    scopus 로고
    • Reduction in cardiovascular events with atorvastatin in 2, 532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-lipid-lowering arm (ASCOT-LLA)
    • Sever PS, Poulter NR, Dahlof B, et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: anglo-Scandinavian Cardiac Outcomes Trial-lipid-lowering arm (ASCOT-LLA). Diabetes Care 2005;28:1151-7
    • (2005) Diabetes Care , vol.28 , pp. 1151-1157
    • Sever, P.S.1    Poulter, N.R.2    Dahlof, B.3
  • 7
    • 77549087054 scopus 로고    scopus 로고
    • Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
    • Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735-42
    • (2010) Lancet , vol.375 , pp. 735-742
    • Sattar, N.1    Preiss, D.2    Murray, H.M.3
  • 8
    • 79959428660 scopus 로고    scopus 로고
    • Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A meta-analysis
    • Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011;305:2556-64
    • (2011) JAMA , vol.305 , pp. 2556-2564
    • Preiss, D.1    Seshasai, S.R.2    Welsh, P.3
  • 9
    • 79953183649 scopus 로고    scopus 로고
    • Predictors of new-onset diabetes in patients treated with atorvastatin: Results from 3 large randomized clinical trials
    • Waters DD, Ho JE, DeMicco DA, et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol 2011;57:1535-45
    • (2011) J Am Coll Cardiol , vol.57 , pp. 1535-1545
    • Waters, D.D.1    Ho, J.E.2    Demicco, D.A.3
  • 10
    • 84880322489 scopus 로고    scopus 로고
    • Food and Drug Administration. FDA drug safety communication: important safety label changes to cholesterol-lowering statin drugs
    • Food and Drug Administration. FDA drug safety communication: important safety label changes to cholesterol-lowering statin drugs. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm 2012
    • (2012)
  • 11
    • 0029914622 scopus 로고    scopus 로고
    • Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
    • Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12
    • (1996) Control Clin Trials , vol.17 , pp. 1-12
    • Jadad, A.R.1    Moore, R.A.2    Carroll, D.3
  • 12
    • 0041876133 scopus 로고    scopus 로고
    • Measuring inconsistency in meta-analyses
    • Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60
    • (2003) BMJ , vol.327 , pp. 557-560
    • Higgins, J.P.1    Thompson, S.G.2    Deeks, J.J.3
  • 13
    • 82455204681 scopus 로고    scopus 로고
    • Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy
    • Abe M, Maruyama N, Okada K, et al. Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy. J Atheroscler Thromb 2011;18:1018-28
    • (2011) J Atheroscler Thromb , vol.18 , pp. 1018-1028
    • Abe, M.1    Maruyama, N.2    Okada, K.3
  • 14
    • 33845867950 scopus 로고    scopus 로고
    • Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes
    • Jinnouchi Y, Yamagishi S, Takeuchi M, et al. Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes. Clin Exp Med 2006;6:191-3
    • (2006) Clin Exp Med , vol.6 , pp. 191-193
    • Jinnouchi, Y.1    Yamagishi, S.2    Takeuchi, M.3
  • 15
    • 36949016667 scopus 로고    scopus 로고
    • Effect of simvastatin on insulin sensitivity in type 2 diabetic subjects
    • M Zafar Iqbal H, Rashida Q, M Yakoob A, et al. Effect of simvastatin on insulin sensitivity in type 2 diabetic subjects. Pak J Med Sci 2007;23:755-9
    • (2007) Pak J Med Sci , vol.23 , pp. 755-759
    • Zafar Iqbal, H.M.1    Rashida, Q.2    Yakoob, A.M.3
  • 16
    • 1842608809 scopus 로고    scopus 로고
    • Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema
    • Gupta A, Gupta V, Thapar S, et al. Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema. Am J Ophthalmol 2004;137:675-82
    • (2004) Am J Ophthalmol , vol.137 , pp. 675-682
    • Gupta, A.1    Gupta, V.2    Thapar, S.3
  • 17
    • 0030922816 scopus 로고    scopus 로고
    • Bias in meta-analysis detected by a simple, graphical test
    • Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34
    • (1997) BMJ , vol.315 , pp. 629-634
    • Egger, M.1    Davey Smith, G.2    Schneider, M.3
  • 18
    • 34347250805 scopus 로고    scopus 로고
    • The HMG-CoA reductase inhibitor cerivastatin lowers advanced glycation end products in patients with type 2 diabetes
    • Scharnagl H, Stojakovic T, Winkler K, et al. The HMG-CoA reductase inhibitor cerivastatin lowers advanced glycation end products in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2007;115:372-5
    • (2007) Exp Clin Endocrinol Diabetes , vol.115 , pp. 372-375
    • Scharnagl, H.1    Stojakovic, T.2    Winkler, K.3
  • 19
    • 21244455704 scopus 로고    scopus 로고
    • Intense cholesterol lowering therapy with a HMG-CoA reductase inhibitor does not improve nitric oxide dependent endothelial function in type-2-diabetes-A multicenter, randomised, double-blind, three-arm placebo-controlled clinical trial
    • Balletshofer BM, Goebbel S, Rittig K, et al. Intense cholesterol lowering therapy with a HMG-CoA reductase inhibitor does not improve nitric oxide dependent endothelial function in type-2-diabetes-a multicenter, randomised, double-blind, three-arm placebo-controlled clinical trial. Exp Clin Endocrinol Diabetes 2005;113:324-30
    • (2005) Exp Clin Endocrinol Diabetes , vol.113 , pp. 324-330
    • Balletshofer, B.M.1    Goebbel, S.2    Rittig, K.3
  • 20
    • 0037215944 scopus 로고    scopus 로고
    • Atorvastatin improves metabolic control and endothelial function in type 2 diabetic patients: A placebo-controlled study
    • Dalla Nora E, Passaro A, Zamboni PF, et al. Atorvastatin improves metabolic control and endothelial function in type 2 diabetic patients: a placebo-controlled study. J Endocrinol Invest 2003;26:73-8
    • (2003) J Endocrinol Invest , vol.26 , pp. 73-78
    • Dalla Nora, E.1    Passaro, A.2    Zamboni, P.F.3
  • 21
    • 0028301570 scopus 로고
    • Simvastatin in non-insulin-dependent diabetes mellitus: Effect on serum lipids, lipoproteins and haemostatic measures
    • Farrer M, Winocour PH, Evans K, et al. Simvastatin in non-insulin-dependent diabetes mellitus: effect on serum lipids, lipoproteins and haemostatic measures. Diabetes Res Clin Pract 1994;23:111-19
    • (1994) Diabetes Res Clin Pract , vol.23 , pp. 111-119
    • Farrer, M.1    Winocour, P.H.2    Evans, K.3
  • 22
    • 64849083500 scopus 로고    scopus 로고
    • The statins in prevention of coronary heart diseases in type 2 diabetics
    • Heljic B, Velija-Asimi Z, Kulic M. The statins in prevention of coronary heart diseases in type 2 diabetics. Bosn J Basic Med Sci 2009;9:71-6
    • (2009) Bosn J Basic Med Sci , vol.9 , pp. 71-76
    • Heljic, B.1    Velija-Asimi, Z.2    Kulic, M.3
  • 23
    • 0034813740 scopus 로고    scopus 로고
    • A double-blind trial on the effects of atorvastatin on glycemic control in Japanese diabetic patients with hypercholesterolemia
    • Tanaka A, Yamada N, Saito Y, et al. A double-blind trial on the effects of atorvastatin on glycemic control in Japanese diabetic patients with hypercholesterolemia. Clin Chim Acta 2001;312:41-7
    • (2001) Clin Chim Acta , vol.312 , pp. 41-47
    • Tanaka, A.1    Yamada, N.2    Saito, Y.3
  • 24
    • 0036830104 scopus 로고    scopus 로고
    • Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus
    • Freed MI, Ratner R, Marcovina SM, et al. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol 2002;90:947-52
    • (2002) Am J Cardiol , vol.90 , pp. 947-952
    • Freed, M.I.1    Ratner, R.2    Marcovina, S.M.3
  • 25
    • 61849172978 scopus 로고    scopus 로고
    • Effects of high-dose simvastatin therapy on glucose metabolism and ectopic lipid deposition in nonobese type 2 diabetic patients
    • Szendroedi J, Anderwald C, Krssak M, et al. Effects of high-dose simvastatin therapy on glucose metabolism and ectopic lipid deposition in nonobese type 2 diabetic patients. Diabetes Care 2009;32:209-14
    • (2009) Diabetes Care , vol.32 , pp. 209-214
    • Szendroedi, J.1    Anderwald, C.2    Krssak, M.3
  • 26
    • 79952746761 scopus 로고    scopus 로고
    • Effect of simvastatin and fenofibrate on cytokine release and systemic inflammation in type 2 diabetes mellitus with mixed dyslipidemia
    • Krysiak R, Gdula-Dymek A, Okopien B. Effect of simvastatin and fenofibrate on cytokine release and systemic inflammation in type 2 diabetes mellitus with mixed dyslipidemia. Am J Cardiol 2011;107:1010-18.e1
    • (2011) Am J Cardiol , vol.107
    • Krysiak, R.1    Gdula-Dymek, A.2    Okopien, B.3
  • 27
    • 0035700258 scopus 로고    scopus 로고
    • Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia
    • Nakamura T, Ushiyama C, Hirokawa K, et al. Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia. Am J Nephrol 2001;21:449-54
    • (2001) Am J Nephrol , vol.21 , pp. 449-454
    • Nakamura, T.1    Ushiyama, C.2    Hirokawa, K.3
  • 28
    • 0027525673 scopus 로고
    • Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria
    • Nielsen S, Schmitz O, Moller N, et al. Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 1993;36:1079-86
    • (1993) Diabetologia , vol.36 , pp. 1079-1086
    • Nielsen, S.1    Schmitz, O.2    Moller, N.3
  • 29
    • 0028918868 scopus 로고
    • Cholesterol-lowering therapy may retard the progression of diabetic nephropathy
    • Lam KS, Cheng IK, Janus ED, et al. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 1995;38:604-9
    • (1995) Diabetologia , vol.38 , pp. 604-609
    • Lam, K.S.1    Cheng, I.K.2    Janus, E.D.3
  • 30
    • 0035431019 scopus 로고    scopus 로고
    • The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: The DALI study: A double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia
    • Diabetes Atorvastin Lipid Intervention (DALI) Study Group
    • Diabetes Atorvastin Lipid Intervention (DALI) Study Group. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care 2001;24:1335-41
    • (2001) Diabetes Care , vol.24 , pp. 1335-1341
  • 31
    • 46349109182 scopus 로고    scopus 로고
    • Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus: A randomized, parallel-group, placebo-controlled, 8-week study
    • Usharani P, Mateen AA, Naidu MU, et al. Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus: a randomized, parallel-group, placebo-controlled, 8-week study. Drugs R D 2008;9:243-50
    • (2008) Drugs R D , vol.9 , pp. 243-250
    • Usharani, P.1    Mateen, A.A.2    Naidu, M.U.3
  • 32
    • 78649743151 scopus 로고    scopus 로고
    • Impact of atorvastatin and omega-3 ethyl esters 90 on plasma plant sterol concentrations and cholesterol synthesis in type 2 diabetes: A randomised placebo controlled factorial trial
    • Neil HA, Ceglarek U, Thiery J, et al. Impact of atorvastatin and omega-3 ethyl esters 90 on plasma plant sterol concentrations and cholesterol synthesis in type 2 diabetes: a randomised placebo controlled factorial trial. Atherosclerosis 2010;213:512-17
    • (2010) Atherosclerosis , vol.213 , pp. 512-517
    • Neil, H.A.1    Ceglarek, U.2    Thiery, J.3
  • 33
    • 0035082925 scopus 로고    scopus 로고
    • Simvastatin treatment on postprandial hypertriglyceridemia in type 2 diabetes mellitus patients with combined hyperlipidemia
    • Sheu WH, Jeng CY, Lee WJ, et al. Simvastatin treatment on postprandial hypertriglyceridemia in type 2 diabetes mellitus patients with combined hyperlipidemia. Metabolism 2001;50:355-9
    • (2001) Metabolism , vol.50 , pp. 355-359
    • Sheu, W.H.1    Jeng, C.Y.2    Lee, W.J.3
  • 34
    • 0036119959 scopus 로고    scopus 로고
    • Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes
    • Pontrelli L, Parris W, Adeli K, et al. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes. Metabolism 2002;51:334-42
    • (2002) Metabolism , vol.51 , pp. 334-342
    • Pontrelli, L.1    Parris, W.2    Adeli, K.3
  • 35
    • 3242738678 scopus 로고    scopus 로고
    • Atorvastatin improves diabetic dyslipidemia and increases lipoprotein lipase activity in vivo
    • Schneider JG, von Eynatten M, Parhofer KG, et al. Atorvastatin improves diabetic dyslipidemia and increases lipoprotein lipase activity in vivo. Atherosclerosis 2004;175:325-31
    • (2004) Atherosclerosis , vol.175 , pp. 325-331
    • Schneider, J.G.1    Von Eynatten, M.2    Parhofer, K.G.3
  • 36
    • 0037840242 scopus 로고    scopus 로고
    • MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial
    • Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16
    • (2003) Lancet , vol.361 , pp. 2005-2016
    • Collins, R.1    Armitage, J.2    Parish, S.3
  • 37
    • 67650702822 scopus 로고    scopus 로고
    • Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients
    • Sukhija R, Prayaga S, Marashdeh M, et al. Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients. J Investig Med 2009;57:495-9
    • (2009) J Investig Med , vol.57 , pp. 495-499
    • Sukhija, R.1    Prayaga, S.2    Marashdeh, M.3
  • 39
    • 84859847419 scopus 로고    scopus 로고
    • Effects of rosuvastatin and atorvastatin on glycaemic control in Type 2 diabetes-The CORALL study
    • Simsek S, Schalkwijk CG, Wolffenbuttel BH. Effects of rosuvastatin and atorvastatin on glycaemic control in Type 2 diabetes-the CORALL study. Diabet Med 2012;29:628-31
    • (2012) Diabet Med , vol.29 , pp. 628-631
    • Simsek, S.1    Schalkwijk, C.G.2    Wolffenbuttel, B.H.3
  • 40
    • 56349119861 scopus 로고    scopus 로고
    • Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus
    • Yamakawa T, Takano T, Tanaka S, et al. Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb 2008;15:269-75
    • (2008) J Atheroscler Thromb , vol.15 , pp. 269-275
    • Yamakawa, T.1    Takano, T.2    Tanaka, S.3
  • 41
    • 73749087527 scopus 로고    scopus 로고
    • Differing effect of statins on insulin sensitivity in non-diabetics: A systematic review and meta-analysis
    • Baker WL, Talati R, White CM, et al. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract 2010;87:98-107
    • (2010) Diabetes Res Clin Pract , vol.87 , pp. 98-107
    • Baker, W.L.1    Talati, R.2    White, C.M.3
  • 42
    • 33745794259 scopus 로고    scopus 로고
    • Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): Implications in glycaemic control
    • Nakata M, Nagasaka S, Kusaka I, et al. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia 2006;49:1881-92
    • (2006) Diabetologia , vol.49 , pp. 1881-1892
    • Nakata, M.1    Nagasaka, S.2    Kusaka, I.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.